Myriad's Q2 Revenues Increase 21 Percent; New $200M Stock Buyback Program Launched | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics' fiscal second-quarter revenues increased 21 percent year over year, the Salt Lake City firm reported after the close of the market on Tuesday.

Total revenues for the three months ended Dec. 31, 2012 came in at $149.1 million, up from $122.8 million in the year ago period, and beating the average analyst estimate of $143.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.